KRAS Mutation Detection by Real-Time and Digital PCR in Tumor Tissue and Plasma and Its Association with Survival in Stage II–IV Colorectal Cancer: A Kazakhstan Cohort Study
Genes · 31.07.2026 · 17 (8) · 907
DOI: 10.3390/genes17080907 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Genes, online erschienen am 31.07.2026. Verfasst von Timur Nasrytdinov und 11 weiteren Autor:innen. Beteiligte Einrichtung: Operating Theatre, Kazakh Institute of Oncology and Radiology, 91 Abay Ave., Almaty 050000, Kazakhstan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, Adenocarcinoma. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Colorectal cancer (CRC) is molecularly heterogeneous, and the KRAS (Kirsten rat sarcoma viral oncogene homolog) genotype both governs eligibility for anti-EGFR (epidermal growth factor receptor) therapy and carries prognostic weight. Central Asian data are scarce: no Kazakhstani series has described the KRAS variant spectrum, linked it to survival, or reported mutation detection rates across specimen types and PCR platforms.
Methods
We studied 332 patients with morphologically confirmed stage II–IV colorectal adenocarcinoma. KRAS status was determined in formalin-fixed paraffin-embedded (FFPE) tumor tissue by allele-specific real-time PCR (RT-PCR) covering six selected codon 12 and 13 variants. Overall survival (OS) was estimated by the Kaplan–Meier method for the whole cohort and with stage stratification. Separately, mutation detection rates were recorded in three non-overlapping groups of different patients: plasma RT-PCR on the Idylla platform (n = 30), plasma nanoplate digital PCR (dPCR) on QIAcuity One (n = 120), and a routine tissue RT-PCR series (546 evaluable of 550). Because these groups differed in patients, specimen type, and mutation panel, this comparison describes observed detection rates only and supports no inference about analytical sensitivity, specificity, or concordance.
Results
KRAS was mutated in 149/332 tumors (44.9%); codon 12 supplied 80.5% of variants, led by G12D (32.2%), G12V (24.8%) and G13D (19.5%). Median OS did not differ between mutant and wild-type tumors (39.0 vs. 36.6 months; p = 0.40). Variant-level differences were directionally consistent, but none was significant, and all were exploratory and unadjusted for multiplicity. Observed detection rates were 40.3% for tissue RT-PCR (220/546), 13.3% for plasma RT-PCR (4/30; continuity-corrected p = 0.006 vs. tissue), and 50.8% for plasma dPCR (61/120; continuity-corrected p = 0.044, Pearson p = 0.034 vs. tissue). BRAF V600E was detected by plasma dPCR in 11/120 cases (9.1%).
Conclusions
This first Kazakhstani series places KRAS frequency within the internationally reported range and shows that variant-level reporting reveals prognostic structure that a binary call conceals. The higher detection rate seen with plasma dPCR is hypothesis-generating, not evidence of platform superiority, and motivates a prospective paired-sample study with harmonized mutation panels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Operating Theatre, Kazakh Institute of Oncology and Radiology, 91 Abay Ave., Almaty 050000, Kazakhstan.
- Department of Oncology, Asfendiyarov Kazakh National Medical University, Tole-Bi Street 94, Almaty 050012, Kazakhstan.
- Department of Cardiology, City Cardiology Centre, Faculty of Medicine, University of International Business, Abay Ave. 8A, Almaty 050010, Kazakhstan.
- Department of Molecular Biology and Medical Genetics, Asfendiyarov Kazakh National Medical University, Zheltoksan Street 37A, Almaty 050004, Kazakhstan.
- Department of Propaedeutics of Internal Medicine, Asfendiyarov Kazakh National Medical University, 94 Tole Bi Str., Almaty 050012, Kazakhstan.
- Department of General Paediatrics, Children's City Clinical Hospital No. 2 of Almaty, Microdistrict 2, Building 54, Almaty 050062, Kazakhstan.
ORCID-Profile: Dilyara Kaidarova, Saken Khaidarov, Bayan Nurgaliyeva, Slu Izmailova, Marat Rabandiyarov, Askar Aidarov
Zitieren
APA
Nasrytdinov, T., Kaidarova, D., Israilova, V., Khaidarov, S., Nurgaliyeva, B., Izmailova, S., Rapilbekova, G., Rabandiyarov, M., Abdygalyk, B., Aidarov, A., Aidarov, D., & Aidarova, A. (2026). KRAS Mutation Detection by Real-Time and Digital PCR in Tumor Tissue and Plasma and Its Association with Survival in Stage II–IV Colorectal Cancer: A Kazakhstan Cohort Study. Genes, 17(8), 907. https://doi.org/10.3390/genes17080907
Vancouver
Nasrytdinov T, Kaidarova D, Israilova V, Khaidarov S, Nurgaliyeva B, Izmailova S, et al. KRAS Mutation Detection by Real-Time and Digital PCR in Tumor Tissue and Plasma and Its Association with Survival in Stage II–IV Colorectal Cancer: A Kazakhstan Cohort Study. Genes. 2026;17(8):907. doi:10.3390/genes17080907
BibTeX
@article{Nasrytdinov2026,
author = {Nasrytdinov, Timur and Kaidarova, Dilyara and Israilova, Venera and Khaidarov, Saken and Nurgaliyeva, Bayan and Izmailova, Slu and Rapilbekova, Gulmira and Rabandiyarov, Marat and Abdygalyk, Bibigul and Aidarov, Askar and Aidarov, Daulet and Aidarova, Aray},
title = {KRAS Mutation Detection by Real-Time and Digital PCR in Tumor Tissue and Plasma and Its Association with Survival in Stage II–IV Colorectal Cancer: A Kazakhstan Cohort Study},
journal = {Genes},
year = {2026},
volume = {17},
number = {8},
pages = {907},
doi = {10.3390/genes17080907}
}
EUVIMED